GASTROMARK
LOE Approachingferumoxsil
NDAORALSUSPENSION
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 21h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GASTROMARK (ferumoxsil) is an oral suspension diagnostic agent containing ultrasmall superparamagnetic iron oxide particles used to enhance MRI visualization of the gastrointestinal tract. It works by accumulating in the bowel lumen and producing susceptibility artifacts that improve lesion detection and staging. The drug enables non-invasive imaging of inflammatory bowel disease, neoplasms, and other GI pathology.
LOE Approaching
As loss of exclusivity approaches, the brand team is likely consolidating focus on retained indications and managed decline strategies, with reduced headcount and budget allocation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GASTROMARK offers limited new career growth opportunities given its LOE-approaching status and minimal linked job openings. Professionals joining this product should expect a defensive, cost-containment-focused role managing decline and maximizing remaining patent life value rather than driving expansion.
Product ManagerDiagnostic Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.